ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

Shares of Bio-Techne Corp. advanced 5.19% to $57.60 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.77% to 6,890.07 and the ...

Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial.

Investing.com -- Gossamer Bio (NASDAQ:GOSS) shares fell 80% Monday after the company’s seralutinib failed to meet the primary endpoint in its Phase 3 PROSERA trial for pulmonary arterial hypertension.

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Nuvation Bio upgraded to Hold as IBTROZI adoption improves, but competition and pipeline risks loom. Click here to read my ...

Nuvation Bio enrolled the first patient in a late-stage study of Ibtrozi. The bigger story, though, was a Wall Street analyst's initiation of coverage on the stock. Shares of Nuvation Bio (NYSE: NUVB) ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...